Evidence map›Paper›PMID 37745122›Full record

ArticleFrontiers in cardiovascular medicine2023

Dipyridamole and vascular healing following stent implantation.

Trevor Simard, Richard Jung, Pietro Di Santo, Alisha Labinaz, Spencer Short, Pouya Motazedian, Shan Dhaliwal, Dhruv Sarma, Adil Rasheed, F Daniel Ramirez and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Trevor Simard *Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Richard Jung *CAPITAL research group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Pietro Di SantoCAPITAL research group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Alisha LabinazCAPITAL research group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Spencer ShortCAPITAL research group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Pouya MotazedianCAPITAL research group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Shan DhaliwalCAPITAL research group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Dhruv SarmaDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Adil RasheedCAPITAL research group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
F Daniel RamirezCAPITAL research group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Michael FroeschlCAPITAL research group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Marino LabinazCAPITAL research group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
David R HolmesDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Mohamad AlkhouliDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Benjamin HibbertDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients undergoing coronary stent implantation incur a 2% annual rate of adverse events, largely driven by in-stent restenosis (ISR) due to neointimal (NI) tissue proliferation, a process in which smooth muscle cell (SMC) biology may play a central role. Dipyridamole (DP) is an approved therapeutic agent with data supporting improved vascular patency rates. Pre-clinical data supports that DP may enact its vasculoprotective effects via adenosine receptor-A2B (ADOR-A2B). We sought to evaluate the efficacy of DP to mitigate ISR in a pre-clinical rabbit stent model. Methods & Results: 24 New Zealand White Rabbits were divided into two cohorts-non-atherosclerosis and atherosclerosis ( Conclusion: Dipyridamole reduces NI proliferation and improves stent healing in a preclinical model of stent implantation with conventional antiplatelets. Atherosclerosis attenuates the observed effect. Clinical trials of DP as an adjunctive agent may be warranted to evaluate for clinical efficacy in stent outcomes.

Indexed as

adenosineadenosine receptor 2Bdipyridamolein-stent restenosis (ISR)neointimaoptical coherence tomograhy (OCT)proliferation and apoptosisvascular smooth muscle (VSMC)

Identifiers

PMID37745122
PMCPMC10514894

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.